Two Clinical Trials on the Kagocel Drug Were Entered into the International Research Database ClinicalTrials.gov
The results of two post-registration clinical trials on the efficacy of the antiviral drug Kagocel were posted in the international clinical trial database ClinicalTrials.gov
A study done in the 2017 epidemiological season called “The Clinical and Epidemiological Efficacy of a Late Interferon Inducer to Prevent Acute Respiratory Viral Infections and influenza in the 2017-2018 Pre-Epidemic Period” (Kagocel for the Prevention of ARVI and Influenza in Adult Health Care Workers) showed that, against the backdrop of preventive treatment with the drug Kagocel, there is a reliable pattern among medical workers who work directly with patients with influenza and acute respiratory viral infections showing that bacterial complications that require prescribing antibacterial drugs are less likely to develop. It was reliably established that during the observation period in the control group some of the subjects that did not take Kagocel suffered from respiratory viral infections two times. There were no patients like this in the main group that took Kagocel. The drug treatment process was tolerated well.
The study “Evaluating the Preventive Effect of a Late Interferon Inducer Against Acute Respiratory Viral Infections in Young People” (Kagocel for the Prevention of ARVI and Influenza in Young People) was observational, non-interventional, and devoted to using the drug Kagocel to help prevent acute respiratory viral infections and influenza during the epidemic rise in the incidence rates in 2018 among people 20-26 years old. It showed that patients who were not administered any drugs to prevent acute respiratory viral infections and influenza had a high (40%) incidence rate for respiratory infections or influenza. In contrast to that, for a 28-day preventive treatment course that involved taking the drug, the incidence rate for respiratory infections or influenza was only 16%. Moreover, when contrasted with preventive treatment using drug Kagocel, the duration for acute respiratory viral infections or influenza in patients was significantly shorter than without prophylaxis using any drugs. The clinical symptoms for upper respiratory viral infections in patients that took Kagocel were observed significantly less frequently than in the control group, were less pronounced, and corresponded to a mild degree of progression for the disease.
In both instances, additional data were obtained for safety on the antiviral drug Kagocel. Now the complete scope of research data is available not only to the professional community in Russia, but also to the international community at large, which is in keeping with best practices in the pharmaceutical industry.
It is worth reiterating that the ClinicalTrials.gov website was created in 2000 by the US National Institute of Health (NIH) in conjunction with the US Food and Drug Administration (US FDA), and is a recognized international source of information on the development and research work that has been accomplished on the efficacy and safety of drugs and medical products. ClinicalTrials.gov contains data from nearly 358,000 clinical trials throughout 218 countries.
Publishing the descriptions of research protocols in an international database makes this information publicly available to medical and pharmaceutical professionals, regulatory authorities, and patients and their families. The data is available to anyone who is interested.
In 2016, ClinicalTrials.gov had already posted an international post-registration study called “Treatment of Influenza in Routine Clinical Practice (FLU-EE)” that was done on the drug Kagocel. That has now been supplemented by two more studies.
Nearmedic Pharma is a Russian pharmaceutical, biotechnology, and healthcare company that was founded in 1989. It is a manufacturer of diagnostic testing systems and original pharmaceutical drugs, including the antiviral drug KAGOCEL®, and is the general distributor for the COLLOST® rejuvenating complex. Nearmedic delivers laboratory equipment manufactured by the world’s leading producers for the Russian domestic market, does after-sales service, and also develops a network of multidisciplinary clinics to provide integrated healthcare services.
For additional information, please visit www.nearmedic.ru/en